Eli Lilly Expands Insilico AI Drug Discovery Deal to $2.75 Billion

Eli Lilly and Company expanded its partnership with Insilico Medicine in a deal worth up to $2.75 billion, according to Reuters. The Financial Times first reported the agreement.

Insilico will receive $115 million upfront, with additional payments tied to development, regulatory, and commercial milestones, Reuters reported. The total deal value could reach approximately $2.75 billion, excluding tiered royalties on future sales, the company said.

Eli Lilly will receive an exclusive worldwide license to develop, manufacture, and commercialize certain oral drug candidates currently in preclinical development, Reuters reported. The agreement covers multiple programs across therapeutic areas, The Wall Street Journal reported.

The companies will also collaborate on research and development programs using Insilico’s Pharma.AI platform, with targets selected by Eli Lilly, The Wall Street Journal reported. The platform is used to identify biological targets and design new drug candidates using machine learning models.